• 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 1029.
  • 2
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 527.
  • 3
    Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological. Cancer 2006; 95: S105S143.
  • 4
    Benedetti-Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 2008; 100: 17071716.
  • 5
    ASTEC Study Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomized study. Lancet 2009; 373: 125136.
  • 6
    Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995; 56: 2933.
  • 7
    Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998; 71: 340343.
  • 8
    Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001; 82: 371374.
  • 9
    Cragun JM, Havrilesky LJ, Calingaert B et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005; 23: 36683675.
  • 10
    Lutman CV, Havrilesky LJ, Cragun JM et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006; 102: 9297.
  • 11
    Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS. The outcome of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007; 106: 282288.
  • 12
    Abu-Rustum NR, Iasonos A, Zhou Q et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol 2008; 198: 455.e14555; discussion 457.e5–6.
  • 13
    Mariani A, Webb MJ, Galli L, Podratz KC. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 2000; 76: 348356.
  • 14
    Candiani GB, Belloni C, Maggi R, Colombo G, Frigoli A, Carinelli SG. Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I. Gynecol Oncol 1990; 37: 68.
  • 15
    Bar-Am A, Ron IG, Kuperminc M et al. The role of routine pelvic lymph node sampling in patients with stage I endometrial carcinoma: Second thoughts. Acta Obstet Gynecol Scand 1998; 77: 347350.
  • 16
    Sartori E, Gaddicci A, Landoni F et al. Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001; 11: 430437.
  • 17
    Hidaka T, Kato K, Yonezawa R et al. Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol 2007; 33: 8690.
  • 18
    Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival Effect of Para-aortic Lymphadenectomy in Endometrial Cancer (SEPAL Study): A retrospective cohort analysis. Lancet 2010; 375: 11651172.
  • 19
    Watari H, Mitamura T, Moriwaki M et al. Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer 2009; 19: 15851590.
  • 20
    Kyo S, Hashimoto M, Maida Y et al. Analysis of outcome of stage I-III endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy. Eur J Gynaec Oncol 2007; 28: 170173.
  • 21
    Fisher B. The revolution in breast cancer surgery: Science or anecdotalism? World J Surg 1985; 9: 655666.
  • 22
    Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009; 105: 109.
  • 23
    Fujimoto T, Najyo H, Nakamura A et al. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol 2007; 107: 253259.
  • 24
    Todo Y, Kato H, Minobe S et al. A validation study of the new revised FIGO staging system to estimate prognosis for patients with stage IIIC endometrial cancer. Gynecol Oncol 2011; 121: 126130.
  • 25
    Todo Y, Kato H, Minobe S et al. Initial failure site according to primary treatment with or without para-aortic lymphadenectomy in endometrial cancer. Gynecol Oncol 2011; 121: 314318.
  • 26
    Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in woman with high-risk endometrial cancer: Results of a pilot study. Gynecol Oncol 1996; 62: 169173.
  • 27
    Niikura H, Okamura C, Utsunomiya H et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol 2004; 92: 669674.
  • 28
    Mariani A, Dowdy SC, Cliby WA et al. Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging. Gynecol Oncol 2008; 109: 1118.
  • 29
    Fotopoulou C, Savvatis K, Kraetschell R, Schefold JC, Lichtenegger W, Sehouli J. Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: Lymph-node mapping and identification of predictive factors for lymph-node status. Eur J Obstet Gynecol Reprod Biol 2010; 149: 199203.
  • 30
    Orr JW Jr, Holloway RW, Orr PF, Holimon JL. Surgical staging of uterine cancer: An analysis of perioperative morbidity. Gynecol Oncol 1991; 42: 209216.
  • 31
    Larson DM, Johnson K, Olson KA. Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: Morbidity and mortality. Obstet Gynecol 1992; 79: 9981001.
  • 32
    Kodama J, Seki N, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y. Risk factors for early and late postoperative complications of patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2006; 124: 222226.
  • 33
    Konnno Y, Todo Y, Minobe S et al. A retrospective analysis of postoperative complications with or without para-aortic lymphadenectomy in endometrial cancer. Int J Gynecol Cancer 2011; 21: 385390.
  • 34
    Füller J, Guderian D, Köhler C, Schneider A, Wendt TG. Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer. Strahlenther Onkol 2008; 184: 206211.
  • 35
    Tada H, Teramukai S, Fukushima M, Sasaki H. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC Cancer 2009; 9: 47.
  • 36
    Gol M, Saygili U, Saatli B, Uslu T, Erten O. Should advanced age alone be considered a contraindication to systemic lymphadenectomy in gynecologic oncologic patients? A university hospital experience in Turkey. Int J Gynecol Cancer 2004; 14: 508514.
  • 37
    Fujita K, Nagano T, Suzuki A et al. Incidence of postoperative ileus after paraaortic lymph node dissection in patients with malignant gynecologic tumors. Int J Clin Oncol 2005; 10: 187190.
  • 38
    Fagotti A, Fanfani F, Ercoli A, Giordano MA, Sallustio G, Scambia G. Postoperative ileus after para-aortic lymphadenectomy: A prospective study. Gynecol Oncol 2007; 104: 4651.
  • 39
    International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology 2003; 36: 8491.
  • 40
    Levenback CF, van der Zee AG, Rob L et al. Sentinel lymph node biopsy in patients with gynecological cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol 2009; 114: 151156.
  • 41
    Abu-Rustum NR, Alekitar K, Iasonos A et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103: 714718.
  • 42
    Abu-Rustum NR, Barakat RR. Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. Gynecol Oncol 2007; 106: 45.
  • 43
    Hoffman MS, Parsons M, Gunasekaran S, Cavanagh D. Distal external iliac lymph nodes in early cervical cancer. Obstet Gynecol 1999; 94: 391394.
  • 44
    Matsumoto K, Yoshikawa H, Yasugi T et al. Distinct lymphatic spread of endometrial carcinoma in comparison with cervical and ovarian carcinomas. Cancer Lett 2002; 180: 8389.
  • 45
    Todo Y, Yamamoto R, Minobe S et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 2010; 119: 6064.
  • 46
    Ohba Y, Todo Y, Kobayashi N et al. Risk factors for lower-limb lymphedema after surgery for cervical cancer. Int J Clin Oncol 2011; 16: 238243.
  • 47
    Hareyama H, Ito K, Hada K et al. Reduction/prevention of lower extremity lymphedema after pelvic and para-aortic lymphadenectomy for patients with gynecologic malignancies. Ann Surg Oncol 2012; 19: 268273.
  • 48
    Todo Y, Kato H, Okamoto K et al. Incidence of metastasis in circumflex iliac nodes distal to the external iliac nodes in intermediate- and high-risk endometrial cancer. Gynecol Oncol 2011; 122: 5558.